Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Chief Medical Officer | November 04, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date November 04, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 954 |
Ending reported balance
After 2022-11-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-11-04 · Exercise / conversion · Acquired 402 · Balance 1,146 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2022-11-07 · Sale · Disposed 192 · Balance 954 F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,427 |
Reported balance
After 2022-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-04 · Exercise / conversion · Disposed 402 · Balance 4,427 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2022 Filed Nov 8, 2022 16:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 192 | $158.68 | $30,466.89 |
DisclosureSEC source: 0001127602-22-025107 · form4.xml · nonDerivative · entry 2 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 16:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025107 · form4.xml · derivative · entry 3 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,427 Underlying: Common Stock · 402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 16:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 402 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025107 · form4.xml · nonDerivative · entry 1 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 16:44 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 865 | $185.10 | $160,107.35 |
DisclosureSEC source: 0001127602-22-020732 · form4.xml · nonDerivative · entry 2 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:44 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,609 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020732 · form4.xml · derivative · entry 3 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Underlying: Common Stock · 1,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:44 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,609 | $194.18 | $312,435.62 |
DisclosureSEC source: 0001127602-22-020732 · form4.xml · nonDerivative · entry 1 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:03 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 10,990 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017895 · form4.xml · derivative · entry 4 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,990 Underlying: Common Stock · 10,990 shares Expires not disclosed F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award will vest on June 16, 2025 and the remaining 50% will vest on June 16, 2026, subject to the recipient's continued service. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award will vest on June 16, 2025 and the remaining 50% will vest on June 16, 2026, subject to the recipient's continued service. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:03 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 19,772 | $0.00 Strike: $121.08 | $0.00 |
DisclosureSEC source: 0001127602-22-017895 · form4.xml · derivative · entry 3 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,772 Underlying: Common Stock · 19,772 shares Expires 2032-06-16 F3 · derivative.exercise_date: 50% of this option will vest and become exercisable on June 16, 2025 and the remaining 50% will vest and become exercisable on June 16, 2026, subject to the recipient's continued service. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:03 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 3,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017895 · form4.xml · derivative · entry 2 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,663 Underlying: Common Stock · 3,663 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:03 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 6,902 | $0.00 Strike: $121.08 | $0.00 |
DisclosureSEC source: 0001127602-22-017895 · form4.xml · derivative · entry 1 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,902 Underlying: Common Stock · 6,902 shares Expires 2032-06-16 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:00 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 1,603 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008043 · form4.xml · derivative · entry 2 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,603 Underlying: Common Stock · 1,603 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:00 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 6,505 | $0.00 Strike: $149.52 | $0.00 |
DisclosureSEC source: 0001127602-22-008043 · form4.xml · derivative · entry 1 Burton Paul · CIK 0001869869 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,505 Underlying: Common Stock · 6,505 shares Expires 2032-03-01 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.